权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

The Role of PI3Kbeta in Breast Cancer Metastasis

PI3Kbeta 在乳腺癌转移中的作用

基本信息

批准号：
9324335
负责人：
ANNE R BRESNICK
金额：
$ 35.4万
依托单位：
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-08-01 至 2020-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9324335
关键词：
1-Phosphatidylinositol 3-Kinase Actins Affect Alpha Cell Apoptosis Binding Binding Sites Biochemical Biological Biology Blood Vessels Breast Cancer Model Breast Cancer Prevention Breast cancer metastasis Cell Proliferation Cell Survival Cells Chemicals Complex Coupling Data Defect Development Dimerization Disease Progression Drug Targeting Enzymes Epithelial Extracellular Matrix Extravasation G Protein-Coupled Receptor Signaling G-Protein-Coupled Receptors Genetic Genetic Models Growth Factor Histology Human Immune system In Vitro Integrins Invaded Knock-in Mouse Link Malignant Neoplasms Mammary gland Measures Mediating Membrane Metabolism Metastatic Neoplasm to the Lung Metastatic breast cancer Modeling Mouse Mammary Tumor Virus Mus Mutant Strains Mice Mutate Mutation Neoplasm Metastasis Normal Cell PIK3CA gene PIK3CG gene PTEN gene Paracrine Communication Penetrance Peptides Pharmaceutical Preparations Phenotype Phosphotransferases Play Prevention approach Primary Neoplasm Production Proteins Recruitment Activity Role S-Phase Fraction SCID Mice Signal Transduction Site Source Stromal Cells Stromal Neoplasm Structure System Testing Therapeutic Tissues Tumor Cell Invasion Tyrosine Work Xenograft Model base cancer cell chemokine cytokine design dimer experimental study gene product human disease in vivo inhibitor/antagonist insight macrophage malignant breast neoplasm mortality mouse model mutant neoplastic cell novel public health relevance src Homology Region 2 Domain tumor tumor growth tumor progression

项目摘要

DESCRIPTION (provided by applicant): Tumor metastasis is the major cause of mortality in human breast cancer. Previous studies have shown that breast cancer metastasis is driven by paracrine signaling between tumor cells and stromal cells, which promotes invasion, intravasation, extravasation and tumor growth at secondary sites. This paracrine signaling is dependent on the reciprocal production of growth factors, cytokines and chemokines produced by stromal cells and tumor cells, many of which signal via G-protein-coupled receptors (GPCRs). We now present extensive preliminary data showing that GPCR signaling to PI3Kβ is critical for tumor cell invasion, intravasation and extravasation. Importantly, loss of GPCR signaling to PI3Kβ has a more severe phenotype on tumor intravasation and extravasation in vivo than loss of kinase activity, suggesting that inhibition of p110β-Gβγ binding might provide an alternative therapeutic approach for the prevention of breast cancer metastasis. This proposal examines the role of PI3Kβ in breast cancer metastasis, using both in vitro and in vivo approaches. The first aim comprises mechanistic studies to evaluate the role of PI3Kβ in the formation of invadopodia, which allow tumor cells to invade into surrounding tissue. We will focus on two models of p110β function in invadopodia maturation: (a) as a local source of PI[3,4,5]P3, whose metabolism to PI[3,4]P2 recruits the critical invadopodia protein Tks5; and (b) as a regulator of integrin signaling, which is important for invadopodia maturation and MMP secretion. Aim 2 examines how p110β integrates upstream signals from GPCRs, RTKs and Rac1, and examines the role of Rac1 signaling to PI3Kβ in breast cancer metastasis. In particular, we find that mutation of the Gβγ binding site in p110β has no effect on Rac1GTP binding and activation of p110β in vitro, but blocks PI3Kβ activation by constitutively active Ra1 in cells. Similarly, inhibitors that block the binding of the p85 regulatory subunit to tyrosine-phosphorylated proteins also inhibit PI3Kβ activation by CA-Rac. We will explore two hypotheses to explain these data: first, that Rac binding to PI3Kβ in cells requires the targeting of PI3Kβ to the membrane, and second, that activation of PI3Kβ by Gβγ or SH2-mediated interactions sensitizes PI3Kβ to Rac. We will also directly test the role of Rac binding to p110β in breast cancer metastasis using in vitro and in vivo xenograft models. Finally, we will study the role of PI3Kβ in breast cancer metastasis using an established genetic mouse model, MMTV-PyMT, which develops mammary epithelial tumors with high penetrance and has an intact immune system. We will cross PyMT mice to a knock-in mouse expressing the GPCR-uncoupled mutant of p110β, to definitively establish the role of GPCR signaling to PI3Kβ in tumor progression and metastasis. Altogether, these studies will lead to important new insights into the basic biology of PI3Kβ, and the role of this complex signaling enzyme in breast cancer metastasis.